Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study

(2016) Susanna Mandruzzato et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

(2016) M. Sade-Feldman et al.   CLINICAL CANCER RESEARCH

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

(2016) Chrisann Kyi et al.   Immunotherapy

Predictive immune markers in advanced melanoma patients treated with ipilimumab

(2016) Viktor Umansky et al.   OncoImmunology

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression

(2015) Laura Pinton et al.   Oncotarget

Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

(2015) Jon Bjoern et al.   OncoImmunology

Myeloid-derived suppressor cell heterogeneity in human cancers

(2014) Samantha Solito et al.   Annals of the New York Academy of Sciences

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

(2014) Sander Kelderman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Complexity and challenges in defining myeloid-derived suppressor cells

(2014) Vera Damuzzo et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

(2014) Ahmad A. Tarhini et al.   PLoS One

T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection

(2014) Marcus Buggert et al.   PLoS Pathogens

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

(2014) J. Yuan et al.   Cancer Immunology Research

Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

(2014) S. Kitano et al.   Cancer Immunology Research

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

(2013) P. A. Ascierto et al.   CLINICAL CANCER RESEARCH

STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients

(2013) David Vasquez-Dunddel et al.   JOURNAL OF CLINICAL INVESTIGATION

Differential Localization of T-bet and Eomes in CD8 T Cell Memory Populations

(2013) L. M. McLane et al.   JOURNAL OF IMMUNOLOGY

Which drug, and when, for patients with BRAF-mutant melanoma?

(2013) Sekwon Jang et al.   LANCET ONCOLOGY

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

(2013) Xin Yao et al.   PHARMACOLOGY & THERAPEUTICS

Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production

(2013) Y. P. de Coana et al.   Cancer Immunology Research

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

(2012) Wenshi Wang et al.   Journal of Translational Medicine

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells

(2011) S. Solito et al.   BLOOD

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma

(2011) Jeffrey S. Weber et al.   JOURNAL OF IMMUNOTHERAPY

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor

(2010) Ilaria Marigo et al.   IMMUNITY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells

(2010) M. G. Lechner et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer

(2009) Chien-Ying Liu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

(2009) Hong Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA